Novogene Fully Upgrades, Launches National Recruitment for "All Age Groups + All Departments + Multi-Platform" Genetic Testing Product Matrix in China

From birth defect prevention and control to early tumor screening, from rare disease diagnosis to precision medication guidance, genetic testing has completed the process of "moving from the laboratory to clinical practice" and is now transitioning from an "optional test" to a "clinical necessity," becoming the infrastructure for multidisciplinary diagnosis and treatment.

VCBeat learned that Novogene, a leading company in gene technology, has completed a key strategic iteration — with the official release of the CNV-Seq+STR combined detection product, its genetic diagnosis product line has achieved a full upgrade, forming a cost-effective solution covering "all age groups, all departments, and multiple platforms."

Recently, Novogene has launched a nationwide business recruitment plan in China, sincerely inviting medical institutions, channel distributors, and health platforms to jointly explore the growing market of precision medicine.

The upgraded CNV-Seq+STR combined detection marks Novogene's transformation from "single-point breakthrough" to "full-line coverage," completing the full-scenario product matrix for genetic diagnosis.

Starting from the application-side demand, the combined CNV-Seq+STR test offers a one-stop solution covering aneuploidy, CNV, polyploidy, and targeted region UPD, while shortening the testing cycle to 5-7 calendar days and upgrading to a more visually informative report template. This single test addresses diverse genetic diagnostic needs without requiring multiple submissions, supporting rapid clinical decision-making.

At the same time, cost and cost-effectiveness are further optimized. The integrated detection system that combines CNV-Seq and STR analysis can reduce consumable costs, improve abnormal detection rates, and offer significantly better cost-effectiveness than traditional solutions; it requires a low amount of sample DNA, features a high level of automation, and does not require cell culture. While reducing experimental operation errors and lowering technical barriers, it also enhances cost controllability.

Unlike the agency model for single test items, Novogene this time opens a "genetic diagnosis + health screening" dual-track product system, forming a comprehensive and multi-option promotion model. Agents can flexibly combine according to their own channel resources and scenario needs, directly meeting the rigid demands of front-line channels:

· Full age range coverage、All DepartmentsPenetration:

During the embryonic/fetal stage, Novogene offers CNV-Seq+STR (for abortus tissue), prenatal CNV-seq, and non-invasive prenatal testing (NIPT); during the neonatal/childhood stage, it covers whole exome sequencing (WES) and Panel testing, which can effectively identify disease-related genetic variations and improve clinical diagnosis and treatment efficiency; for adults, it provides personal genome, carrier screening, and cancer gene testing to meet diverse health needs across all adult stages. Thus, its products can be applied in various departments such as the laboratory, obstetrics and gynecology, pediatrics, NICU, genetic metabolism department, and assisted reproduction department, adapting to multiple clinical scenarios, thereby...Breaking the limitations of single-department agency models to achieve full lifecycle management from embryo to adulthood.

· Genetic diagnosis products focus on solving the clinical pain point of "difficult to confirm diagnosis"

For high-precision demands, WES (Whole Exome Sequencing) can detect over 20,000 genes in one test, addressing undiagnosed genetic disorders and rare diseases, meeting the diagnostic needs of complex cases in tertiary hospitals; WGS (Whole Genome Sequencing) is suitable for variant detection across the entire genome, applicable to the diagnosis of complex genetic disorders.

In terms of popularization needs in grassroots hospitals and physical examination centers, CNV-seq (low-depth whole genome sequencing) is suitable for detecting chromosomal copy number variations in abortion tissues and prenatal samples, with reports available in 5 to 7 days; Panel (targeted gene package), on the other hand, can provide customized testing solutions for specific diseases.

· Health Screening Solutions Target the "Preventive Healthcare" Market Growth

Consumer-grade genetic testing, such as personal genome services, covers scenarios like nutritional metabolism, sports genes, and medication guidance; it also provides single-gene hereditary disease carrier screening for couples planning to conceive, aligning with China's national policy direction on birth defect prevention and control.

Novogene (688315) was founded in March 2011, focusing on the application of cutting-edge molecular biology technologies and high-performance computing in life science research and human health fields, and is committed to becoming a global leading provider of genomics products and services.In April 2021, Novogene was listed on the STAR Market of the Shanghai Stock Exchange, becoming the "first stock in gene research services."

As a leading player in the fields of gene sequencing, proteomics, and metabolomics, Novogene's businesses cover basic life science research services, medical research and technical services, and library construction and sequencing platform services. It provides reliable multi-omics solutions for research universities, scientific research institutes, hospitals, pharmaceutical R&D enterprises, and agricultural companies worldwide.

After 15 years of深耕 in gene technology, Novogene's business spans more than 90 countries and regions across six continents, with laboratories and subsidiaries established in China, the UK, Singapore, and other places, serving over 7,300 customers. It has established extensive collaborations with numerous academic institutions; as of June 2025, it has co-authored or been mentioned in 34,570 SCI articles. It has obtained 547 software copyrights and 112 patents.

Based on profound R&D accumulation and industrial chain strength, Novogene provides channel partners with not only a gene testing matrix product but also a full-process solution that is compliant, efficient, and professional.

· Compliance Qualification Moat:Novogene and its multiple laboratories have obtained international certifications such as CAP (College of American Pathologists), ISO 13485 (Medical Device Quality Management System), ISO 9001, and ISO 15189 (Accreditation for Quality and Competence of Medical Laboratories), building a compliance moat for hospital entry.

· Fast Delivery Time:Whole Exome Sequencing (WES) achieves stable delivery in 12 calendar days; CNV-seq achieves delivery in 5 to 7 calendar days. In real-world scenarios, difficult cases in neonatal intensive care and the gestational window for prenatal diagnosis both have extremely high requirements for testing turnaround time, and delivery speed will directly translate into product advantages and clinical competitiveness.

· Multi-regional collaborative delivery:The three major laboratories in Tianjin, Shanghai, and Guangzhou form a collaborative production capacity and联动delivery. This not only ensures testing throughput and timeliness but also provides regional logistics and service response advantages for channel partners, reducing the risk of sample transportation.

· Multi-scenario Clinical Coverage:A diversified product matrix covers core department applications such as the laboratory, obstetrics and gynecology, pediatrics, NICU, genetic metabolism, and assisted reproduction. Distributors can leverage existing channels for multi-department penetration, enhancing the value of individual customers.

· Professional Team Support:A high-throughput, large-scale gene sequencing platform and high-performance computing platform have been established, with proprietary databases and a high-quality comprehensive service team, providing in-depth and precise guideline analysis and report annotation.

· Customized After-sales Service:With a professional team providing pre-sales, mid-sales, and after-sales support, the technical service threshold for channel partners is reduced throughout the entire process. For example, customized report templates, professional report interpretation, and genetic counseling are provided for different clinical scenarios.

From "single-product agency" to "platform-based cooperation," and from "single-department penetration" to "full age group coverage," Novogene has not only achieved a complete product line upgrade but also redefined the "combination-type" channel cooperation model, creating a more imaginative market space. For medical channel distributors, choosing to cooperate with a leading platform that offers full qualifications, a complete product range, fast delivery, and strong service capabilities is a crucial step in building competitive barriers in the era of precision medicine.